Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(2146)
•••
Comment by jdstoxon Feb 16, 2018 1:16pm
208 Views
Post# 27573499

RE:RE:RE:2018 requirements

RE:RE:RE:2018 requirementsjekyl, about my relationship with Bioasis, it's well known, old news. I attended the roadshows across Western Canada. Met a lot of people. Everyone knows who I am or can find out just by asking. I am completely exposed to the public and I am available to the public at all times.

And you know what, jekyl, a lot of people know who you are, too, especially people in Edmonton and Calgary. It's only a matter of time until you upset enough people, badly enough, that somebody goes on the record about who you and your buddies are. Stock promoters who sell their stock to their "friends" don't keep those friends for very long.

About waiting for a "long long long time," like I suggested yesterday, jekyl, if that's what you believe, then bet on it. regardless made the same "prediction." Neither of you can back the claim. That's two of the many ways that you and regardless are alike.

jdstox

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities